Does Tecovirimat Monohydrate Interact with Repaglinide?
CDI records a moderate classification for Tecovirimat Monohydrate and Repaglinide. The stored summary is: TPOXX increases repaglinide concentration. Monitor blood glucose and hypoglycemic symptoms when co-administered. The mechanism involves tecovirimat is a weak inhibitor of cyp2c8, which metabolizes repaglinide. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Tecovirimat Monohydrate Class
- Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor
- Repaglinide Class
- Glinide
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Tecovirimat is a weak inhibitor of CYP2C8, which metabolizes repaglinide
What To Tell Your Doctor or Pharmacist
If you are taking Tecovirimat Monohydrate and your doctor is considering prescribing Repaglinide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider